Lesional Macrophage‐Targeted Nanomedicine Regulating Cholesterol Homeostasis for the Treatment of Atherosclerosis
Advanced Materials · 2025-09 · 37 (37)
DOI: 10.1002/adma.202502581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 27.06.2025. Verfasst von Boyu Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipi-ents and Departm…. Hauptthemen laut MEDLINE: Cholesterol, Atherosclerosis, Homeostasis, Macrophages. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The accumulation of atherosclerosis plaques within arterial walls leads to cardiovascular events. Lipid‐laden macrophages, known as foam cells play a pivotal role in atherosclerotic plaque progression by disrupting cholesterol homeostasis and facilitating inflammation. This study presents a rational and multivalent nanoplatform ( siT TENPs) for atherosclerosis treatment. siT TENPs can form electrostatic complexes with the nucleic acid siTRPM2 , thereby reducing oxidized low‐density lipoprotein (oxLDL) uptake by foam cells and alleviating inflammation. Concurrently, β‐cyclodextrin (β‐CD) modified siT TENPs facilitate cholesterol clearance, further re‐establishing lipid homeostasis. The nanometer size and S2P peptide (CRTLLTVRKC) modification endow these particles with specific targeting capabilities toward lesional macrophages, thereby enhancing their anti‐atherosclerotic efficacy. Consequently, the siT TENPs delivery system effectively inhibits pathological cholesterol internalization while simultaneously promoting cholesterol efflux mechanisms and reducing inflammation. This therapeutic intervention leads to significant regression of atherosclerotic plaque. This study introduces an innovative therapeutic strategy aimed at improving cholesterol homeostasis, with promising implications for the treatment of atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipi-ents and Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical Univers…
- Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi, Guizhou, 56300, China.
ORCID-Profile: Lei Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, B., Zhu, L., Lei, L., Li, H., Cong, R., Hou, J., Zhao, J., Li, P., Tang, Y., Su, Z., Tu, J., & Jiang, L. (2025). Lesional Macrophage‐Targeted Nanomedicine Regulating Cholesterol Homeostasis for the Treatment of Atherosclerosis. Advanced Materials, 37(37). https://doi.org/10.1002/adma.202502581
Vancouver
Liu B, Zhu L, Lei L, Li H, Cong R, Hou J, et al. Lesional Macrophage‐Targeted Nanomedicine Regulating Cholesterol Homeostasis for the Treatment of Atherosclerosis. Advanced Materials. 2025;37(37). doi:10.1002/adma.202502581
BibTeX
@article{Liu2025,
author = {Liu, Boyu and Zhu, Lei and Lei, Lei and Li, Huifang and Cong, Rui and Hou, Jinfan and Zhao, Jiehui and Li, Pengwei and Tang, Yiwei and Su, Zhigui and Tu, Jiasheng and Jiang, Lei},
title = {Lesional Macrophage‐Targeted Nanomedicine Regulating Cholesterol Homeostasis for the Treatment of Atherosclerosis},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {37},
doi = {10.1002/adma.202502581}
}
EUVIMED